← Human Trials & Peer-Reviewed Studies
Timing of Carbetocin Administration in Postpartum Hemorrhage
Plain-language guide to NCT06776926: not phased randomized trial of Carbetocin, 200 participants. Who took part, design and what was measured.
Key Facts
- Registry ID
- NCT06776926
- Phase
- not phased
- Status
- completed
- Start
- 2025-01-10
- Completion (planned or actual)
- 2025-02-28
- Participants
- 200 (actual)
- Design
- randomized, open label (everyone knows who gets what), diagnostic
- Conditions studied
- Postpartum Hemorrhage; Carbetocin
- Results posted
- not yet
What This Study Did, in Plain Language
What Was Tested
In this not phased trial, researchers set out to test Carbetocin.
Postpartum haemorrhage (PPH) is one of the major contributors to maternal mortality and morbidity worldwide.
It had two arms (groups): After placenta is delivered (experimental) and Before placenta is delivered (experimental).
The group that received carbetocin after placenta delivery.
The group that received carbetocin before placenta delivery.
The registry classes the interventions as behavioral.
Who Took Part
The registry lists 200 actual participants took part.
It was open to women only aged from 18 years up to 40 years.
Healthy volunteers could join, not only people with the condition.
Examples of who could join: Vaginal delivery at or beyond 38 weeks of gestation.
The full record lists 3 inclusion and 9 exclusion criteria; among the exclusions: contraindications to carbetocin use (e.g., pre-existing hypertension, pre-eclampsia,asthma, cardiac, renal, or liver disease); high-risk factors for primary postpartum hemorrhage, including grand multiparity,presence of uterine fibroids, or a need for prophylactic oxytocin infusion; anemia or.
How the Study Was Run
Design: randomized, single-group and open-label.
Because people in this Carbetocin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Being open-label, the Carbetocin study did not mask who received what.
Everyone received the same intervention, so there was no separate comparison group inside the trial.
It started in 2025-01-10 with completion listed for 2025-02-28.
It ran at 1 site in Turkey (Türkiye).
Its stated primary purpose is diagnostic.
What Was Measured
The main thing measured (primary outcome): Carbetosin effect (time frame: 24 hours after delivery).
What This Means in Plain Language
Put simply, this is a not phased, randomized trial of Carbetocin in 200 people.
The trial is marked completed; no results are posted to the registry yet, so nothing here describes outcomes.
More context: the Carbetocin compound page, all human trials.
Our Notes on the Compound
Carbetocin: A long-acting oxytocin analog used outside the US to prevent bleeding after childbirth; also studied intranasally in Prader-Willi syndrome.
Related Pages
Source: ClinicalTrials.gov record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.